{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:26Z","timestamp":1790739806520,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11910-007-0046-y","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T03:46:10Z","timestamp":1184643970000},"page":"302-310","source":"Crossref","is-referenced-by-count":47,"title":["Levodopa-induced Dyskinesia in Parkinson\u2019s disease: Epidemiology, etiology, and treatment"],"prefix":"10.1007","volume":"7","author":[{"given":"Theresa A.","family":"Zesiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,12]]},"reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M. Pechevis","year":"2005","unstructured":"Pechevis M, Clarke CE, Vieregge P, et al.; Trial Study Group: Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005, 12:956\u2013963.","journal-title":"Eur J Neurol"},{"key":"46_CR2","first-page":"163","volume":"52","author":"M.D. Muenter","year":"1977","unstructured":"Muenter MD, Sharpless NS, Tyce GM, Darley FL: Patterns of dystonia (\u201cI-D-I\u201d and \u201cD-I-D\u201d) in response to L dopa therapy for Parkinson\u2019s disease. Mayo Clin Proc 1977, 52:163\u2013174.","journal-title":"Mayo Clin Proc"},{"key":"46_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00002826-200111000-00002","volume":"24","author":"O. Rascol","year":"2001","unstructured":"Rascol O, Fabre N: Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001, 24:313\u2013323.","journal-title":"Clin Neuropharmacol"},{"key":"46_CR4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archneur.1975.00490470075011","volume":"32","author":"H.L. Klawans","year":"1975","unstructured":"Klawans HL, Goetz C, Bergen D: Levodopa-induced myoclonus. Arch Neurol 1975, 32:330\u2013334.","journal-title":"Arch Neurol"},{"issue":"Suppl1","key":"46_CR5","first-page":"13","volume":"14","author":"M. Vidailhet","year":"1999","unstructured":"Vidailhet M, Bonnet AM, Marconi R: The phenomenology of L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 1999, 14(Suppl 1):13\u201318.","journal-title":"Mov Disord"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870090103","volume":"9","author":"R. Marconi","year":"1994","unstructured":"Marconi R, Lefebvre-Caparros D, Bonnet AM, et al.: Levodopa-induced dyskinesias in Parkinson\u2019s disease: phenomenology and pathophysiology. Mov Disord 1994, 9:2\u201312.","journal-title":"Mov Disord"},{"key":"46_CR7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1008928321652","volume":"9","author":"A.M. Damiano","year":"2000","unstructured":"Damiano AM, McGrath MM, William MK, et al.: Evaluation of a measurement strategy for Parkinson\u2019s disease: assessing patient health-related quality of life. Qual Life Res 2000, 9:87\u2013100.","journal-title":"Qual Life Res"},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A. Schrag","year":"2000","unstructured":"Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain 2000, 123:2297\u20132305.","journal-title":"Brain"},{"issue":"3Suppl3","key":"46_CR9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.50.3_Suppl_3.S1","volume":"50","author":"C. W. Olanow","year":"1998","unstructured":"Olanow C W, Koller WC: An algorithm (decision tree) for the management of Parkinson\u2019s disease: treatment guidelines. American Academy of Neurology. Neurology 1998, 50(3 Suppl 3):S1\u2013S57.","journal-title":"Neurology"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"J.E. Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448\u2013458.","journal-title":"Mov Disord"},{"key":"46_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","volume":"63","author":"J.A. Gerpen Van","year":"2006","unstructured":"Van Gerpen JA, Kumar N, Bower JH, et al.: Levodop-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990. Arch Neurol 2006, 63:205\u2013209.","journal-title":"Arch Neurol"},{"key":"46_CR12","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S. Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, et al.: Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 2004, 351:2498\u20132508.","journal-title":"N Engl J Med"},{"key":"46_CR13","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","volume":"21","author":"O. Rascol","year":"2006","unstructured":"Rascol O, Brooks DJ, Korczyn AD, et al.; 056 Study Group: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006, 21:1844\u20131850.","journal-title":"Mov Disord"},{"key":"46_CR14","first-page":"1044","volume":"61","author":"R.G. Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, et al.: Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61:1044\u20131053.","journal-title":"Arch Neurol"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00702-006-0603-6","volume":"114","author":"S. Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Mash DC: Motor fluctuations and dyskinesias in advanced\/end stage Parkinson\u2019s disease: a study from a population of brain donors. J Neural Transm 2007, 114:341\u2013345.","journal-title":"J Neural Transm"},{"key":"46_CR16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.62.4.601","volume":"62","author":"M. Zappia","year":"2005","unstructured":"Zappia M, Annesi G, Nicoletti G, et al.: Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. Arch Neurol 2005, 62:601\u2013605.","journal-title":"Arch Neurol"},{"key":"46_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.parkreldis.2006.07.002","volume":"12","author":"J.C. Sharma","year":"2006","unstructured":"Sharma JC, Macnamara L, Hasoon M, et al.: Cascade of levodopa dose and weight-related dyskinesia in Parkinson\u2019s disease (LD-WD-PD cascade). Parkinsonism Relat Disord 2006, 12:499\u2013505.","journal-title":"Parkinsonism Relat Disord"},{"key":"46_CR18","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","volume":"63","author":"R.A. Hauser","year":"2006","unstructured":"Hauser RA, McDermott MP, Messing S: Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006, 63:1756\u20131760.","journal-title":"Arch Neurol"},{"key":"46_CR19","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W. Guy","year":"1976","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Government Printing Office; 1976."},{"key":"46_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mds.870090403","volume":"9","author":"C.G. Goetz","year":"1994","unstructured":"Goetz CG, Stebbins GT, Shale HM, et al.: Utility of an objective dyskineisa rating scale for Parkinson\u2019s disease: inter-and intrarater reliability assessment. Mov Disord 1994, 9:390\u2013394.","journal-title":"Mov Disord"},{"key":"46_CR21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/mds.20248","volume":"19","author":"R.A. Hauser","year":"2004","unstructured":"Hauser RA, Deckers F, Lehert P: Parkinson\u2019s disease home diary: further validation and implications for clinical trials. Mov Disord 2004, 19:1409\u20131413.","journal-title":"Mov Disord"},{"key":"46_CR22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"R.A. Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, et al.: A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000, 23:75\u201381.","journal-title":"Clin Neuropharmacol"},{"key":"46_CR23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","volume":"54","author":"S. Konitsiotis","year":"2000","unstructured":"Konitsiotis S, Blanchet PJ, Verhagen L, et al.: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000, 54:1589\u20131595.","journal-title":"Neurology"},{"key":"46_CR24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O. Rascol","year":"2001","unstructured":"Rascol O, Arnulf I, Saint P, et al.: Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 2001, 16:708\u2013713.","journal-title":"Mov Disord"},{"key":"46_CR25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F. Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829\u20131834.","journal-title":"Neurology"},{"key":"46_CR26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","volume":"177","author":"J.D. Oh","year":"2002","unstructured":"Oh JD, Bibbiani F, Chase TN: Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 2002, 177:557\u2013564.","journal-title":"Exp Neurol"},{"key":"46_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"C.W. Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F: Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677\u2013687.","journal-title":"Lancet Neurol"},{"key":"46_CR28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","volume":"11","author":"E.P. Silva-Junior da","year":"2005","unstructured":"da Silva-Junior EP, Braga-Neto P, Sueli Monte F, de Bruin VM: Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005, 11:449\u2013452.","journal-title":"Parkinsonism Relat Disord"},{"key":"46_CR29","first-page":"141","volume":"75","author":"A. Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, et al.: Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2004, 75:141\u2013143.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"46_CR30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56","author":"L.V. Metman","year":"1999","unstructured":"Metman LV, Del Dotto P, LePoole K, et al.: Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999, 56:1383\u20131386.","journal-title":"Arch Neurol"},{"key":"46_CR31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.25.7.603","volume":"25","author":"J.F. Butzer","year":"1975","unstructured":"Butzer JF, Silver DE, Sahs AL: Amantadine in Parkinson\u2019s disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975, 25:603\u2013606.","journal-title":"Neurology"},{"key":"46_CR32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L. Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, et al.: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 1998, 50:1323\u20131326.","journal-title":"Neurology"},{"key":"46_CR33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1586\/14737175.6.10.1403","volume":"6","author":"D. Nyholm","year":"2006","unstructured":"Nyholm D: Enteral levodopa\/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinsons\u2019s disease. Expert Rev Neurother 2006, 6:1403\u20131411","journal-title":"Expert Rev Neurother"},{"key":"46_CR34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-200305000-00010","volume":"26","author":"D. Nyholm","year":"2003","unstructured":"Nyholm D, Askmark H, Gomes-Trolin C, et al.: Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003, 26:156\u2013163.","journal-title":"Clin Neuropharmacol"},{"key":"46_CR35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D. Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AI, Dizdar N, et al.: Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64:216\u2013223.","journal-title":"Neurology"},{"key":"46_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000117399","volume":"37","author":"G. Block","year":"1997","unstructured":"Block G, Liss C, Reines S, et al.: Comparison of immediate-release and controlled release carbidopa\/levodopa in Parkinson\u2019s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997, 37:23\u201327.","journal-title":"Eur Neurol"},{"key":"46_CR37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.parkreldis.2005.03.005","volume":"11","author":"A. Storch","year":"2005","unstructured":"Storch A, Trenkwalder C, Oehlwein C, et al.: High-dose treatment with pergolide in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias. Parkinsonism Relat Disord 2005, 11:393\u2013398.","journal-title":"Parkinsonism Relat Disord"},{"key":"46_CR38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1471-4159.1993.tb05831.x","volume":"60","author":"S. Kaakkola","year":"1993","unstructured":"Kaakkola S, Wurtman RJ: Effects of catechol-O-methyl-transferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 1993, 60:137\u2013144.","journal-title":"J Neurochem"},{"key":"46_CR39","first-page":"491","volume":"80","author":"U.K. Rinne","year":"1999","unstructured":"Rinne UK, Gordin A, Teravainen H: COMT inhibition with entacapone in the treatment of Parkinson\u2019s disease. Ann Neurol 1999, 80:491\u2013494.","journal-title":"Ann Neurol"},{"key":"46_CR40","volume-title":"Parkinson\u2019s Disease: Questions and Answers","author":"A. Theresa","year":"2006","unstructured":"Theresa A, Zesiewicz TA, Lyons KE, et al.: Parkinson\u2019s Disease: Questions and Answers, edn 5. Edited by Robert A. Hauser. West Palm Beach, Florida: Merit Publishing International; 2006.","edition":"edn 5."},{"key":"46_CR41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mds.20780","volume":"21","author":"C. Marin","year":"2006","unstructured":"Marin C, Aguilar E, Obeso JA: Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov Disord 2006, 21:646\u2013653.","journal-title":"Mov Disord"},{"key":"46_CR42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mds.20317","volume":"20","author":"L.A. Smith","year":"2005","unstructured":"Smith LA, Jackson MJ, Al-Barghouthy G, et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005, 20:306\u2013314.","journal-title":"Mov Disord"},{"key":"46_CR43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(00)00105-9","volume":"391","author":"W. Loscher","year":"2000","unstructured":"Loscher W, Richter A: Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 2000, 391:251\u2013254.","journal-title":"Eur J Pharmacol"},{"key":"46_CR44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/mds.10542","volume":"18","author":"M.P. Hill","year":"2003","unstructured":"Hill MP, Bezard E, McGuire SG, et al.: Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003, 18:1301\u20131305.","journal-title":"Mov Disord"},{"key":"46_CR45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.20563","volume":"20","author":"T.A. Zesiewicz","year":"2005","unstructured":"Zesiewicz TA, Sullivan KL, Maldonado JL, et al.: Openlabel pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 2005, 20:1205\u20131209.","journal-title":"Mov Disord"},{"key":"46_CR46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.WNF.0000220814.48360.F4","volume":"29","author":"K.E. Lyons","year":"2006","unstructured":"Lyons KE, Pahwa R: Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006, 29:148\u2013153.","journal-title":"Clin Neuropharmacol"},{"key":"46_CR47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","volume":"319","author":"M.M. Iravani","year":"2006","unstructured":"Iravani MM, Tayarani-Binazir K, Chu WB, et al.: In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\/increased motor disability. J Pharmacol Exp Ther 2006, 319:1225\u20131234.","journal-title":"J Pharmacol Exp Ther"},{"key":"46_CR48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"C.G. Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, et al.: Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22:179\u2013186.","journal-title":"Mov Disord"},{"key":"46_CR49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F. Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, et al.: Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004, 62:381\u2013388.","journal-title":"Neurology"},{"key":"46_CR50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.1998.tb05955.x","volume":"97","author":"F. Pierelli","year":"1998","unstructured":"Pierelli F, Adipietro A, Soldati G, et al.: Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 1998, 97:295\u2013299.","journal-title":"Acta Neurol Scand"},{"key":"46_CR51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mds.870090406","volume":"9","author":"J.P. Bennett Jr","year":"1994","unstructured":"Bennett JP Jr, Landow ER, Dietrich S, Schuh LA: Suppression of dyskinesias in advanced Parkinson\u2019s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994, 9:409\u2013414.","journal-title":"Mov Disord"},{"key":"46_CR52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.20738","volume":"59","author":"P. Samadi","year":"2006","unstructured":"Samadi P, Gregoire L, Rouillard C, et al.: Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 2006, 59:282\u2013288.","journal-title":"Ann Neurol"},{"key":"46_CR53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.870130307","volume":"13","author":"L. Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Blanchet PJ, van den Munckhof P, et al.: A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998, 13:414\u2013417.","journal-title":"Mov Disord"},{"key":"46_CR54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1212\/WNL.51.1.203","volume":"51","author":"L. Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, Natte R, et al.: Dextromethorphan improves levodopa-induced dyskinesias in Parkinson\u2019s disease. Neurology 1998, 51:203\u2013206.","journal-title":"Neurology"},{"issue":"Suppl11","key":"46_CR55","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/mds.20480","volume":"20","author":"L.V. Metman","year":"2005","unstructured":"Metman LV, O\u2019Leary ST: Role of surgery in the treatment of motor complications. Mov Disord 2005, 20(Suppl 11):S45\u201356.","journal-title":"Mov Disord"},{"key":"46_CR56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMoa000827","volume":"345","author":"Deep-Brain Stimulation for Parkinson\u2019s Disease Study Group","year":"2001","unstructured":"Deep-Brain Stimulation for Parkinson\u2019s Disease Study Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson\u2019s disease. N Engl J Med 2001, 345:956\u2013963.","journal-title":"N Engl J Med"},{"key":"46_CR57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/1531-8257(199901)14:1<50::AID-MDS1010>3.0.CO;2-6","volume":"14","author":"M. Merello","year":"1999","unstructured":"Merello M, Nouzeilles MI, Kuzis G, et al.: Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: a prospective randomized comparison. Mov Disord 1999, 14:50\u201356.","journal-title":"Mov Disord"},{"key":"46_CR58","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3171\/jns.2004.100.6.0997","volume":"100","author":"M. Ogura","year":"2004","unstructured":"Ogura M, Nakao N, Nakai E, et al.: The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. J Neurosurg 2004, 100:997\u20131001.","journal-title":"J Neurosurg"},{"key":"46_CR59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3171\/jns.2001.94.1.0043","volume":"94","author":"A. Alkhani","year":"2001","unstructured":"Alkhani A, Lozano AM: Pallidotomy for Parkinson\u2019s disease: a review of contemporary literature. J Neurosurg 2001, 94:43\u201349.","journal-title":"J Neurosurg"},{"key":"46_CR60","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ana.10517","volume":"53","author":"J.L. Vitek","year":"2003","unstructured":"Vitek JL, Bakay RA, Freeman A, et al.: Randomized trial of pallidotomy versus medical therapy for Parkinson\u2019s disease. Ann Neurol 2003, 53:558\u2013569.","journal-title":"Ann Neurol"},{"issue":"Suppl14","key":"46_CR61","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1002\/mds.20962","volume":"21","author":"G. Kleiner-Fisman","year":"2006","unstructured":"Kleiner-Fisman G, Herzog J, Fisman DN, et al.: Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006, 21(Suppl 14):S290\u2013304.","journal-title":"Mov Disord"},{"key":"46_CR62","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G. Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P; German Parkinson Study Group, Neurostimulation Section: A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 2006, 355:896\u2013908.","journal-title":"N Engl J Med"},{"key":"46_CR63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mds.10188","volume":"17","author":"K. Ostergaard","year":"2002","unstructured":"Ostergaard K, Sunde N, Dupont E: Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson\u2019s disease and motor fluctuations. Mov Disord 2002, 17:693\u2013700.","journal-title":"Mov Disord"},{"key":"46_CR64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3171\/jns.2003.99.1.0071","volume":"99","author":"R. Pahwa","year":"2003","unstructured":"Pahwa R, Wilkinson SB, Overman J, Lyons KE: Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 2003, 99:71\u201377.","journal-title":"J Neurosurg"},{"key":"46_CR65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/01.WNL.0000103235.12621.C3","volume":"62","author":"R.A. Esselink","year":"2004","unstructured":"Esselink RA, de Bie RM, de Haan RJ, et al.: Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004, 62:201\u2013207.","journal-title":"Neurology"},{"issue":"Suppl1","key":"46_CR66","first-page":"S193","volume":"47","author":"A.E. Lang","year":"2000","unstructured":"Lang AE: Surgery for levodopa-induced dyskinesias. Ann Neurol 2000, 47(Suppl 1):S193\u2013S199; discussion S199\u2013S202.","journal-title":"Ann Neurol"},{"key":"46_CR67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa035275","volume":"349","author":"P. Krack","year":"2003","unstructured":"Krack P, Batir A, Van Blercom N, et al.: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N Engl J Med 2003, 349:1925\u20131934.","journal-title":"N Engl J Med"},{"key":"46_CR68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"C.R. Freed","year":"2001","unstructured":"Freed CR, Greene PE, Breeze RE, et al.: Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med 2001, 344:710\u2013719.","journal-title":"N Engl J Med"},{"key":"46_CR69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"C.W. Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH, et al.: A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol 2003, 54:403\u2013414.","journal-title":"Ann Neurol"},{"key":"46_CR70","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","volume":"52","author":"Y. Ma","year":"2002","unstructured":"Ma Y, Feigin A, Dhawan V, et al.: Dyskinesia after fetal cell transplantation for Parkinsonism: a PET study. Ann Neurol 2002, 52:628\u2013634.","journal-title":"Ann Neurol"},{"key":"46_CR71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P. Hagell","year":"2002","unstructured":"Hagell P, Piccini P, Bjorkland A, et al.: Dyskinesias following neural transplantation in Parkinson\u2019s disease. Nat Neurosci 2002, 5:627\u2013628.","journal-title":"Nat Neurosci"},{"issue":"Suppl1","key":"46_CR72","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000056425","volume":"70","author":"R.F. Young","year":"1998","unstructured":"Young RF, Vermeulen S, Posewitz A, Shumway-Cook A: Pallidotomy with the gamma knife: a positive experience. Stereotact Funct Neurosurg 1998, 70(Suppl 1):218\u2013228","journal-title":"Stereotact Funct Neurosurg"},{"key":"46_CR73","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125","author":"R. Grondin","year":"2002","unstructured":"Grondin R, Zhand Z, Yi A, et al.: Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125:2191\u20132201.","journal-title":"Brain"},{"key":"46_CR74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"S.S. Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, et al.: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589\u2013595.","journal-title":"Nat Med"},{"key":"46_CR75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"A. E. Lang","year":"2006","unstructured":"Lang A E, Gill S, Patel NK, et al.: Randomized controlled trial of intraputamental glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459\u2013466.","journal-title":"Ann Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-007-0046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-007-0046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-007-0046-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:24:38Z","timestamp":1559435078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-007-0046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s11910-007-0046-y","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}